A rare case of pericarditis, complication of infliximab treatment for Crohn's disease

Devasahayam, Joe; Pillai, Unnikrishnan; Lacasse, Alexandre

doi:10.1016/j.crohns.2012.02.016

Cited by 21 publications

(23 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Pericarditis is a very rare, but clinically significant, adverse event related to drugs used to treat inflammatory bowel diseases (IBDs), such as mesalazine, sulfasalazine and azathioprine . Pericarditis has also been recognized as a very rare adverse event that can be associated with the use of infliximab in patients with IBD . The diagnosis of drug‐induced pericarditis is often difficult.…”

Section: What Is Known and Study Objectivementioning

confidence: 99%

Pericarditis during infliximab therapy in paediatric ulcerative colitis

et al. 2017

View full text Add to dashboard Cite

show abstract

Section: What Is Known and Study Objectivementioning

confidence: 99%

Pericarditis during infliximab therapy in paediatric ulcerative colitis

et al. 2017

View full text Add to dashboard Cite

show abstract

“…The connection is usually based on case reports. Currently, it seems that hypersensitive reactions, in particular development of lupus erythematosus, and excessive anticoagulant treatment leading to intrapericardial bleeding are among the most common causes of drug‐developed pericarditis . Several anticancer drugs have a less clear etiology, but hypersensitivity can play a role .…”

Section: Drugs With the Major Effects On The Heartmentioning

confidence: 99%

“…Currently, it seems that hypersensitive reactions, in particular development of lupus erythematosus, and excessive anticoagulant treatment leading to intrapericardial bleeding are among the most common causes of drug-developed pericarditis. [373][374][375][376][377][378][379][380][381][382][383] Several anticancer drugs have a less clear etiology, but hypersensitivity can play a role. [384][385][386] Similarly, pericardial effusion caused by specific bcr-abl tyrosine kinase inhibitors can have an immune background.…”

Section: Drugs Causing Pericarditismentioning

confidence: 99%

Comprehensive review of cardiovascular toxicity of drugs and related agents

Mladěnka

Applová

Patočka

et al. 2018

Medicinal Research Reviews

215

120

View full text Add to dashboard Cite

Cardiovascular diseases are a leading cause of morbidity and mortality in most developed countries of the world. Pharmaceuticals, illicit drugs, and toxins can significantly contribute to the overall cardiovascular burden and thus deserve attention. The present article is a systematic overview of drugs that may induce distinct cardiovascular toxicity. The compounds are classified into agents that have significant effects on the heart, blood vessels, or both. The mechanism(s) of toxic action are discussed and treatment modalities are briefly mentioned in relevant cases. Due to the large number of clinically relevant compounds discussed, this article could be of interest to a broad audience including pharmacologists and toxicologists, pharmacists, physicians, and medicinal chemists. Particular emphasis is given to clinically relevant topics including the cardiovascular toxicity of illicit sympathomimetic drugs (e.g., cocaine, amphetamines, cathinones), drugs that prolong the QT interval, antidysrhythmic drugs, digoxin and other cardioactive steroids, beta‐blockers, calcium channel blockers, female hormones, nonsteroidal anti‐inflammatory, and anticancer compounds encompassing anthracyclines and novel targeted therapy interfering with the HER2 or the vascular endothelial growth factor pathway.

show abstract

“…The other case occurred in psoriatic arthritis with adalimumab; however, pericardial fluid was not drained so the fluid type was unknown [11]. Additionally, a case of pericarditis without effusion occurred in a patient with IBD on infliximab [12]. The presumed pathophysiology in all three patients is a hypersensitivity type III immune-complex reaction.…”

Section: Literature Reviewmentioning

confidence: 99%

“…All but one had RA without purulent effusion; he had IBD and noneffusive pericarditis while on infliximab and he was treated with NSAIDs for 2 weeks and at a later time resumed adalimumab with no problems during follow-up [12]. …”

Section: Literature Reviewmentioning

confidence: 99%

Hemorrhagic Pericardial Effusion with Tamponade: A Rare Adverse Effect of Infliximab—Case Report and Literature Review

Lather

Kahlenberg

2016

Case Reports in Rheumatology

View full text Add to dashboard Cite

Introduction. Antitumor necrosis factor (TNF) alpha agents are commonly used biologic therapies for a wide variety of rheumatic and inflammatory diseases. Here, we present a case of hemorrhagic pericarditis as a consequence of infliximab and review the literature on pericardial complications stemming from this drug class. Methods. For the literature review, search terms using versions of antitumor necrosis factor alpha AND pericardial effusion OR pericarditis OR pleuropericarditis OR cardiac tamponade were used. Results. Pericarditis is a rare but serious complication of anti-TNF based therapy, and hemorrhagic fluid is even more rare, with only one additional case reported. It is likely that this complication was secondary to a robust immune response to very high titer anti-infliximab antibodies. Providers should be aware that this complication can occur and that abnormal elevations in procalcitonin may accompany this unusual finding.

show abstract

A rare case of pericarditis, complication of infliximab treatment for Crohn's disease

Cited by 21 publications

References 8 publications

Pericarditis during infliximab therapy in paediatric ulcerative colitis

Pericarditis during infliximab therapy in paediatric ulcerative colitis

Comprehensive review of cardiovascular toxicity of drugs and related agents

Hemorrhagic Pericardial Effusion with Tamponade: A Rare Adverse Effect of Infliximab—Case Report and Literature Review

Contact Info

Product

Resources

About